Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Cardiac Electrophysiologists (US)

Council Members in this Study Group: 319

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Hossein Ardehali, Assistant Professor, Northwestern University, Feinberg School of MedicineHossein Ardehali

Assistant Professor
Northwestern University, Feinberg School of Medicine
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Hossein Ardehali, MD, PhD, is Assistant Professor of Medicine at Feinberg Cardiovascular Institute in Illinois. His specialties include lipid metabolism, preventive cardiology, electrophysiology and heart failure. Dr. Ardehali's basic science research...

Michael Kim

Associate Professor
Northwestern University, Feinberg School of Medicine
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Michael Kim, MD, is Associate Professor at Feinberg School of Medicine, Northwestern University, Illinois. He has served as Cardiac Electrophysiologist at Health Partners and Regions Hospital in Minnesota and also as Associate Professor at the University...

Daniel Weiss, President, Weiss Consulting Groups, Inc.Daniel Weiss

President
Weiss Consulting Groups, Inc.
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Daniel Weiss, MD, FACC, is a Clinical Cardiac Electrophysiologist with Florida Arrhythmia Consultants and the Founder and President of his own consultancy, Weiss Consulting Groups, which provides consultation services to the business world on medical...

David Martin, Director of the Cardiac Arrhythmia Service , LAHEY CLINICDavid Martin

Director of the Cardiac Arrhythmia Service
LAHEY CLINIC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

David Martin, MD, FRCP, FACC, FACP, FHRS is the Director of the Arrhythmia Service and Program Director of Cardiac Electrophysiology Fellowship at Lahey Clinic in Burlington, Massachusetts. He also holds appointments at Harvard and Tufts medical schools....

Byron Lee

Assistant Professor
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Byron Lee, MD, is an Assistant Professor of Medicine in the Division of Cardiology at University of California San Francisco. Dr. Lee is board certified in Cardiovascular Disease and Clinical Cardiac Electrophysiology. He has expertise in treatments for...

View all Leading Experts in this Study Group

GLG NewsSM Analyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

A new drug that would change the way we treat Atrial Fibrillation!

May 20, 2008

Landmark ATHENA Study findings with dronedarone presented during the annual Heart Rhythm meeting in San Francisco | www.medscape.com

Atrial fibrillation management.  New anti-arrhythmic medication.  

Medtronic - the new Guidant?

October 18, 2007

Medtronic Pulls Heart Device Wires | www.thestreet.com

The current recall is yet another in the world of cardiac rhythm devices. The ICD market is already shakey and may be adversely affected. Will Medtronic's reputation suffer?

TB-402 - the type of anticoagulant patients and physicians are looking for as a warfarin replacement

September 17, 2007

ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 | www.pipelinereview.com

TB-402 is a new anticoagulant candidate that seeks to fill a desperate unmet need in a variety of different medical conditions. It would be easily administered with a low risk of patient noncompliance, have reversible effects, and potentially safer than currently available alternatives.

A lot of fuss about nothing

March 26, 2007

St. Jude Medical Announces FDA Approval of First U.S. Heart Failure Device with AF Suppression Technology | salesandmarketingnetwork.com

1. This technology has been in SJM pacemakers for long enough that we know AF is not eliminated - merely reduced in amount

2. Reduction in AF burden does not translate into reduced need for anticoagulation in this high risk population

3. Reduction in AF burden does not translate into reduction in clinical end-points such as stroke

4. The AF-suppression algorithm increases heart rate significantly and may (in theory) undermine the benefits of CRT

New studies suggest DES may improve outcome in the setting of AMI

September 19, 2006

NEJM Articles on DES in MI | content.nejm.org

The studies reported in the recent issues of NEJM are significant in that they provide evidence that DES in the setting of AMI with ST elevation may improve outcome. Taxel-eluting stents showed nonsignificant improvement in adverse cardiac events, but sirolimus-eluting stents showed a significant reduction in target vessel revascularization

 

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic

Members in this Study Group often have these job titles:

  • Physician - Attending Physician
  • Physician - Director
  • Physician - Division Head
  • Owner
  • Director
  • Partner

GLG Live Meetings with this Study Group's Leading Experts (?)

July 28, 2009 | New York

GLG Seminar: (NYC) Antiarrhythmics with Michael Kim, MD

GLG Webcasts & Teleconferences

Leading Experts in Cardiac Electrophysiologists (US) have not participated in any GLG webcasts.

View All GLG Webcasts & Teleconferences in Healthcare